Teva Pharmaceutical Industries Limited (TEVA:NYSE) closed at $43.79 on November 13, 2026, up 0.31% on the day. The stock trades 1.2% below its 52-week high of $44.31 and 82.4% above its 52-week low of $24.01. Over the past year, it gained 70.9%. Teva Pharmaceutical Industries Limited is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 12, 2025, TEVA closed higher on 127 days (50%). Its best day was April 29, 2026 (+11.89%) and its worst was June 2, 2026 (-4.50%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 2 times.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women's health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson's disease; and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma an...
Find more stocks like TEVA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.